Here are the 10-K annual reports from Ensysce Bioscience WTS (ENSCW) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ENSCW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ENSCW filings page.
Ensysce Biosciences is a clinical-stage pharmaceutical company developing abuse-resistant and overdose-protective opioid pain therapies using its TAAP and MPAR platforms. Lead drug PF614, an extended-release oxycodone prodrug, has completed multiple Phase 1 trials and human abuse potential studies, and a pivotal Phase 3 post-surgical pain trial began enrollment in December 2025.
Combination candidate PF614-MPAR, which adds nafamostat for overdose protection, has shown reduced oxycodone exposure in simulated overdose settings and received FDA Breakthrough Therapy designation in January 2024. The company highlights substantial ongoing losses, a need for significant additional funding, reliance on PF614 and PF614-MPAR, Nasdaq delisting risk, and extensive regulatory and intellectual property uncertainties.